Atomoxetine capsules contain atomoxetine hydrochloride, a selective norepinephrine reuptake inhibitor (SNRI) used in the treatment of attention deficit hyperactivity disorder (ADHD) in adults and children aged 6 and over. Unlike methylphenidate and amphetamine-based ADHD treatments, atomoxetine is a non-stimulant medication and is not a controlled drug under the Misuse of Drugs Act 1971. This makes it an important treatment option for patients in whom stimulant medications are contraindicated, poorly tolerated, or not clinically preferred. Atomoxetine is a prescription-only medicine prescribed at PrimeLife following full diagnostic assessment and clinical review by a specialist ADHD clinician.
How It Works
Atomoxetine selectively inhibits the norepinephrine transporter in the presynaptic neuron, blocking the reuptake of norepinephrine and increasing its availability in the synaptic cleft of neural circuits involved in attention, executive function, and impulse regulation — particularly within the prefrontal cortex. Unlike methylphenidate, atomoxetine has minimal effect on dopamine reuptake in the striatum, which contributes to its significantly lower potential for misuse or dependence. The therapeutic effect of atomoxetine develops gradually over four to six weeks of consistent daily treatment, rather than the rapid onset of symptom improvement seen with stimulant medications. Patients and clinicians should be aware of this delayed onset and should not assess efficacy before an adequate trial period has elapsed.
Why Atomoxetine is an Important ADHD Option
Atomoxetine provides effective ADHD management for patients for whom stimulant-based medications are not appropriate. These include patients with a history of substance misuse for whom a non-scheduled medication is strongly clinically preferred, patients who experience intolerable cardiovascular or anxiety side effects with stimulants, and patients with co-occurring conditions such as anxiety disorders or tic disorders that may be exacerbated by stimulant medications.
The non-controlled drug status of atomoxetine means that prescriptions can be issued as standard prescriptions, which may simplify the prescribing and dispensing process compared to Schedule 2 stimulant preparations. The full-day and into-the-evening symptom coverage that atomoxetine provides makes it particularly suited to patients whose ADHD symptoms are most disruptive during the evening and home environment. Available in 10mg, 18mg, 25mg, 40mg, 60mg, and 80mg capsule strengths to support gradual dose titration from a low starting dose.
Important Note
Atomoxetine is a prescription-only medicine that must be used under specialist supervision. Therapeutic effect develops gradually over four to six weeks — patients should continue treatment for this duration before assessing efficacy. Atomoxetine is contraindicated in patients with narrow-angle glaucoma, serious cardiovascular or cerebrovascular disease, phaeochromocytoma, or those using or within 14 days of stopping MAOIs. There is a specific regulatory warning regarding increased risk of suicidal ideation in children and adolescents during early treatment, requiring close monitoring. Common side effects include nausea, decreased appetite, dry mouth, fatigue, and mood changes. This medication must only be used as directed by a qualified specialist prescriber with regular clinical review.
